4.6 Article

Complement killing of clinical Klebsiella pneumoniae isolates is serum concentration dependent

Journal

MICROBES AND INFECTION
Volume 25, Issue 4, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.micinf.2022.105074

Keywords

Klebsiella pneumoniae; Bacterial capsules; Complement system; Alternative pathway; Membrane attack complex; Serum resistance

Ask authors/readers for more resources

Klebsiella pneumoniae, an opportunistic gram-negative pathogen, was analyzed for serum susceptibility in normal human serum (NHS). The study found that the activation of complement cascades is crucial for killing bacteria in plasma. The concentration-dependent functionality of the alternative pathway (AP) was observed in the killing of the isolates.
Klebsiella pneumoniae is an opportunistic gram-negative pathogen causing serious infections, including sepsis. In plasma, activation of the complement cascades is important for killing bacteria. Thirty clinical Klebsiella spp. blood isolates were analyzed for serum susceptibility in 75% normal human serum (NHS). Twenty-two were serum resistant and eight were serum sensitive, and subsequently tested in 5-75% NHS. Two isolates were killed in 5% and the remaining six in 50%-75% NHS. The two 5% sensitive isolates showed binding of complement (C)4 and C3 in 5% NHS with formation of membrane attack complex (MAC). Inhibition of the classical/lectin mediated pathways (CP/LP) using a C4 specific nanobody, hC4Nb8, led to survival of both isolates in 5% NHS. Using nanobody hC3Nb1, inhibiting the alternative pathway (AP), the isolates were killed in 5% NHS, and amplification of the CP/LP by AP was not necessary for killing. Sole AP killing of these isolates when inhibiting CP/LP with hC4Nb8 was observed in 50% NHS, stressing the concentration dependent functionality of AP. For the less sensitive isolates, killing required activation of CP/LP and AP demonstrated by inhibition with nanobodies. AP inhibition resulted in no C3 deposition on the serum resistant isolate, supporting that AP was the sole activation pathway. (c) 2022 Published by Elsevier Masson SAS on behalf of Institut Pasteur.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available